ReviewOncology letters2019
ST6GAL1: A key player in cancer.
Review in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it, 112 citations in OpenAlex.
- Genome-wide association studies in a large Korean cohort identify quantitative trait loci for 36 traits and illuminate their genetic architectures.Nature communications · 2025Pooled it
- Galectin-3 Mediates TGF-β-Controlled Migration in Müller Glial Cells.International journal of molecular sciences · 2026Article
- Article
- Targeted Strategies for Treatment of Colorectal Cancer: Exploring the Use of Aptamers and Gold Nanoparticles.Molecules (Basel, Switzerland) · 2026Review
- Sulfonylurea Bioisosteres of Sulfonic Acid in JFD 00458-Based ST6GAL1 Inhibitors Enhance Membrane Permeability.ChemMedChem · 2026Article
- ST6GAL1 Is a Functional Regulator of UVA-Induced Photoaging in Human Dermal Fibroblasts.Cells · 2026Article
- The glycobiology of prostate cancer: an update.Oncogene · 2026Review
- Highly branched complex-type N-glycans on integrin β1 in extracellular vesicles enhance the binding of sEVs to laminin on recipient cells.The Journal of biological chemistry · 2026Article
- Severe hypoxia drives loss of ST6GAL1-mediated α2,6-sialylation in the epicardial secretome impairing angiogenic activity.Biology open · 2026Article
- Writers and readers of sialylation in immunoregulation in cancer.The Journal of biological chemistry · 2026Review
- ST6GAL1-mediated sialylation inhibits the antitumor immune response in colorectal cancer.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Review
- Building simplified cancer subtyping and prediction models with glycan gene signatures.Cell reports methods · 2025Article
- Multi-omics reveals that ST6GAL1 promotes colorectal cancer progression through LGALS3BP sialylation.Biomolecules & biomedicine · 2025Article
- M2-Like Macrophages Exhibit Sialic Acid-Enhanced Efferocytosis via the Siglec CD22.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Novel Click Coupling Chemistry to Explore Glycan Recognition.ACS central science · 2025Article
- Combined effect of areca nut, cigarettes, alcohol and SNPs in glycosyltransferase family genes on lung cancer development in Hainan, China.BMC cancer · 2025Article
- Comparative evaluation of methods for isolating extracellular vesicles from ICC cell culture supernatants: Insights into proteomic and glycomic analysis.Cell communication and signaling : CCS · 2025Article
- A novel sialylation pathway mediated by extracellular vesicles in aggressive prostate cancer.PloS one · 2025Article
- GlycoRNA: A new player in cellular communication.Oncology research · 2025Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant glycosylation is a universal feature of cancer cells and there is now overwhelming evidence that glycans can modulate pathways intrinsic to tumour cell biology. Glycans are important in all of the cancer hallmarks and there is a renewed interest in the glycomic profiling of tumours to improve early diagnosis, determine patient prognosis and identify targets for therapeutic intervention. One of the most widely occurring cancer associated changes in glycosylation is abnormal sialylation which is often accompanied by changes in sialyltransferase activity. Several sialyltransferases are implicated in cancer, but in recent years ST6 β-galactoside α-2,6-sialyltransferase 1 (ST6GAL1) has become increasingly dominant in the literature. ST6GAL1 catalyses the addition of α2,6-linked sialic acids to terminal N-glycans and can modify glycoproteins and/or glycolipids. ST6GAL1 is upregulated in numerous types of cancer (including pancreatic, prostate, breast and ovarian cancer) and can promote growth, survival and metastasis. The present review discusses ST6GAL in relation to the hallmarks of cancer, and highlights its key role in multiple mechanisms intrinsic to tumour cell biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.